| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 175,90 | 176,70 | 19:24 | |
| 175,90 | 176,70 | 19:24 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 178,20 | 50 | |||
| 178,00 | 3 | |||
| 177,80 | 3 | |||
| 176,80 | 169 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/56s1.htm [/URL] | ||||
| 169 | 176,00 | |||
| 3 | 175,00 | |||
| 3 | 174,80 | |||
| 3 | 174,60 | |||
| 47 | 174,40 | |||
| 1.023 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.248 | 0,180 | 225 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:09:05 | 176,70 | 9 |
| 13:19:51 | 175,10 | 2 |
| 09:04:53 | 175,90 | 1 |
| Tagesumsatz Xetra | -0,70 -0,40 % | 118 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 319 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 06.05. | RBC stuft Sartorius Stedim Biotech auf 'Outperform' | 633 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Sartorius Stedim mit einem Kursziel von 210 Euro auf "Outperform" belassen. Analyst Charles Weston nahm mit Blick auf die jüngsten Quartalszahlen... ► Artikel lesen | |
| 05.05. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 387 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH Aktie jetzt für 0€ handeln | |||||
| 23.04. | BARCLAYS stuft Sartorius Stedim Biotech auf 'Overweight' | 768 | dpa-AFX-Analyser | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Sartorius Stedim nach Zahlen auf "Overweight" mit einem Kursziel von 220 Euro belassen. Umsatz und bereinigtes... ► Artikel lesen | |
| 23.04. | Sartorius Stedim Biotech S.A. GAAP EPS of €0.91, revenue of €761.5M | 3 | Seeking Alpha |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 18:06 | RedHill Biopharma Ltd.: RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | PR Newswire | Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma... ► Artikel lesen | |
| 14:54 | Arcus Biosciences In Clinical Trial Collaboration With Bristol Myers Squibb For Renal Cell Carcinoma | AFX News | NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Wednesday a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY).Under... ► Artikel lesen | |
| 15:09 | EQS-News: GeoVax, Inc.: GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation | EQS Group (EN) | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation 03.06.2026 / 15:06 CET/CEST
The... ► Artikel lesen | |
| 14:06 | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | GlobeNewswire (Europe) | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| 14:02 | Ainos, Inc.: Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / June 3, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence... ► Artikel lesen |